JD Supra: Mergers

SEPTEMBER 6, 2023

For years, the antitrust enforcement agencies have indicated their antipathy toward resolving competition issues in proposed mergers by entering into consent decrees that prohibit certain conduct, rather than stopping the merger entirely or fixing the competition issues through divestitures. By: Mintz - Antitrust Viewpoints

Mergers 172

Mergers Pharmaceutical IT 172

JD Supra: Mergers

JULY 10, 2024

Cephalon, Inc., 2018-0075-SG (Del. 30, 2024) - Stockholder representatives of an acquired corporation brought claims alleging that defendants had failed to use contractually-required commercially reasonable efforts to commercialize an acquired drug asset for a particular use. By: Morris James LLP

Pharmaceutical 161

Pharmaceutical Mergers Corporation 161

Global Newswire by Notified: M&A

MARCH 20, 2024

Nika Pharmaceuticals, Inc. OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.

Pharmaceutical 89

Pharmaceutical Mergers IT 89

Global Newswire by Notified: M&A

MAY 13, 2024

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology

Mergers 53

Mergers Pharmaceutical Portfolio 53

Global Newswire by Notified: M&A

JULY 9, 2024

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger

Mergers 61

Mergers Pharmaceutical Stock 61

JD Supra: Mergers

MAY 26, 2023

On May 17, 2023, the Federal Trade Commission (FTC) challenged Amgen Inc.’s s (Amgen) proposed acquisition of Horizon Therapeutics plc (Horizon). The complaint is significant in three respects. By: Wilson Sonsini Goodrich & Rosati

Mergers 130

Mergers Pharmaceutical Trading Acquisitions 130

Global Newswire by Notified: M&A

OCTOBER 6, 2023

PRESIDIO PROPERTY TRUST ANNOUNCES CLOSING OF MERGER OF ITS SPONSORED SPAC MURPHY CANYON ACQUISITION CORP NOW TRADING AS CONDUIT PHARMACEUTICALS.

Pharmaceutical 40

Pharmaceutical Mergers and Acquisitions Mergers Trading 40

JD Supra: Mergers

SEPTEMBER 4, 2024

August 01, 2024: SEAM Group, a B2B business products and services company that provides safety, reliability, maintenance, and enterprise asset management services in the hospitality, food processing, and pharmaceutical industries, was acquired by ABB for an undisclosed amount.

M&A 167

M&A Hospitality Asset Management Pharmaceutical 167

Global Newswire by Notified: M&A

JULY 23, 2024

The Company reports steady progress in its due diligence efforts and, contingent upon meeting all regulatory requirements, anticipates completing the Proposed Transaction by the end of August 2024.

Mergers 40

Mergers Pharmaceutical Medical IT 40

Global Newswire by Notified: M&A

AUGUST 15, 2023

Reverse Stock Split Merger on Track to Close on August 16, 2023 Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5

Mergers 40

Mergers Pharmaceutical Stock 40

Global Newswire by Notified: M&A

JULY 27, 2024

Nasdaq: ALIM ) , relating to its proposed merger with ANI Pharmaceuticals, Inc. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50

M&A 45

M&A Mergers Pharmaceutical Shares 45

JD Supra: Mergers

APRIL 18, 2024

On March 26, 2024, Skadden hosted a discussion on key developments in antitrust enforcement in the pharmaceuticals and life sciences sectors. By: Skadden, Arps, Slate, Meagher & Flom LLP

Pharmaceutical 172

Pharmaceutical 172

JD Supra: Mergers

MAY 15, 2024

Bass, Berry & Sims brought a team of four attorneys from our Specialty Pharmacy & Pharmaceuticals and 340B Program Services practice groups to join the fun. Asembia’s 20th Annual Specialty Pharmacy Summit once again brought investors and operators in the specialty pharmacy ecosystem to Las Vegas for learning sessions and networking.

Pharmaceutical 172

Pharmaceutical Investors 172

JD Supra: Mergers

JULY 10, 2024

Among these are two cross-agency Requests for Information (RFIs) about anticompetitive transactions, an online portal to enable anyone to report anticompetitive business practices, a new Department of Justice (DOJ) task force and a new Federal Trade Commission (FTC) investigation into certain Teva Pharmaceuticals’ patent.

Government 167

Government Pharmaceutical Trading Business 167

JD Supra: Mergers

MARCH 27, 2024

designs and produces solutions for the biopharmaceutical, pharmaceutical and medical device markets and aerospace industries. New Mountain Capital will sell ILC Dover to Ingersoll Rand for about $2.3 billion, according to industry reports. ILC, founded in 1947 and based in Frederica, Del., By: McGuireWoods LLP

Private Equity 155

Private Equity Pharmaceutical Healthcare Medical 155

JD Supra: Mergers

JULY 24, 2023

While the two companies evidently have some history together, this new deal is reportedly tied to Phillip Morris’ interest in acquiring Syqe’s metered-dose, pharmaceutical-grade inhaler that dispenses precise doses of medical cannabis to patients. By: Bradley Arant Boult Cummings LLP

Medical 246

Medical Pharmaceutical 246

JD Supra: Mergers

APRIL 23, 2024

We were fortunate to have a mix of expert perspectives at the table, representing large pharmaceutical companies, investors, By: Mintz Asset Sale,” with business development leaders from GSK, Johnson & Johnson, Locust Walk, and Astria Therapeutics.

Pharmaceutical 167

Pharmaceutical M&A Sale Investors 167

Solganick & Co.

SEPTEMBER 2, 2024

September 2, 2024 – The software mergers and acquisitions (M&A) marketplace has been bustling with activity in the first half of 2024, reflecting the sector’s robust growth and strategic consolidations. per share in cash in a transaction that values the Company at approximately $1.25

Mergers and Acquisitions 52

Mergers and Acquisitions Acquisitions Mergers M&A 52

JD Supra: Mergers

JANUARY 22, 2024

Morgan Healthcare Conference in San Francisco, which also saw the announcement of major acquisitions by large players in the pharmaceutical space. The timing of the announcement coincided with the start of the 42nd Annual J.P. By: Knobbe Martens

Pharmaceutical 177

Pharmaceutical Healthcare Corporation Equities 177

JD Supra: Mergers

JANUARY 26, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022), total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. By: Cooley LLP

M&A 167

M&A Pharmaceutical Business 167

JD Supra: Mergers

FEBRUARY 5, 2024

The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products. Key takeaways are that: EU and Member State authorities imposed multiple material antitrust fines from 2018-2022, totalling approx. EUR780 million. By: Allen & Overy LLP

Medical 167

Medical Pharmaceutical IT 167

JD Supra: Mergers

DECEMBER 1, 2023

To that end, the DOJ recently announced its decision to decline to prosecute Lifecore Biomedical, a pharmaceutical and medical device manufacturer, despite evidence that employees of Lifecore’s former US subsidiary bribed Mexican government officials in violation of the Foreign Corrupt Practices Act.

M&A 167

M&A Pharmaceutical Medical Manufacturing 167

JD Supra: Mergers

MAY 23, 2023

ACN, based in Dallas, is a clinical site platform serving patients, pharmaceutical sponsors and contract research organizations. Amulet Capital Partners has announced it has acquired Alliance Clinical Network (ACN). By: McGuireWoods LLP

Private Equity 130

Private Equity Pharmaceutical Healthcare Equities 130

Devensoft

MAY 25, 2023

Corporate restructuring can be a game-changer for any organization, whether it’s a merger, acquisition, or any other strategic move. Understanding merger vs acquisition Mergers and acquisitions (M&A) are two of the most common forms of corporate restructuring.

Corporation 52

Corporation Mergers Mergers and Acquisitions Acquisitions 52

Shearman & Sterling

JANUARY 8, 2019

. ("Ception") against pharmaceutical company Cephalon, Inc. ("Cephalon"), which acquired Ception, alleging violations of an earn-out provision in their merger agreement. The Court also dismissed an implied covenant claim against Cephalon and tortious interference claims against Teva Pharmaceutical Industries Ltd.

Pharmaceutical 52

Pharmaceutical Mergers Medical IT 52

JD Supra: Mergers

MAY 25, 2023

Our prior updates covered how FTC enforcement activity largely proceeded “as usual” during 2022 in the life sciences industry, with large pharmaceutical players buying or licensing promising, but still risky, assets from clinical- or preclinical-stage companies.

Pharmaceutical 130

Pharmaceutical 130

The Guardian: Mergers & Acquisitions

MARCH 19, 2024

The Anglo-Swedish company struck an agreement to acquire Fusion Pharmaceuticals, which is developing next-generation radioconjugates that offer an alternative to chemotherapy and radiotherapy.

Pharmaceutical 88

Pharmaceutical Portfolio Acquisitions Business 88

The Guardian: Mergers & Acquisitions

DECEMBER 26, 2023

The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease.

Pharmaceutical 77

Pharmaceutical Acquisitions IT Mergers and Acquisitions 77

Shearman & Sterling

JANUARY 8, 2019

. ("Ception") against pharmaceutical company Cephalon, Inc. ("Cephalon"), which acquired Ception, alleging violations of an earn-out provision in their merger agreement. The Court also dismissed an implied covenant claim against Cephalon and tortious interference claims against Teva Pharmaceutical Industries Ltd.

Pharmaceutical 40

Pharmaceutical Mergers Medical IT 40

Benchmark International

APRIL 18, 2024

The healthcare sector is primarily segmented into pharmaceuticals, services, devices, and others. According to Verified Market Research, the global healthcare market will reach $665.37 billion by 2028. By application, the industry is categorized by cardiovascular, oncology, anti-infection, central nervous system, respiratory, and others.

Healthcare 59

Healthcare Medical Pharmaceutical Mergers and Acquisitions 59

Wizenius

APRIL 27, 2023

One specific area where these laws are frequently applied is in the context of merger and acquisition transactions. To prevent this from happening, governments often have laws in place that regulate mergers and acquisitions to ensure that they do not create or enhance a monopoly or otherwise harm competition.

Mergers and Acquisitions 52

Mergers and Acquisitions Pharmaceutical Retail Acquisitions 52

Shearman & Sterling

SEPTEMBER 6, 2016

Bouchard of the Delaware Court of Chancery dismissed a shareholder action seeking post-merger damages for breach of fiduciary duty against the directors and officers of C&J Energy Services, Inc. Slights III of the Delaware Court of Chancery dismissed an action brought by former shareholders of Auspex Pharmaceuticals, Inc.

Mergers 52

Mergers Pharmaceutical M&A Business 52

Cooley M&A

JANUARY 24, 2018

We offer insights on what to expect in the new year, including an increased scrutiny on vertical mergers; a heightened focus on structural remedies in enforcement actions; a continued spotlight on the pharmaceutical industry – particularly with respect to proposed mergers and reverse payment agreements; a potential Supreme Court ruling on the rule (..)

Pharmaceutical 52

Pharmaceutical Mergers Business 52

The Harvard Law School Forum

JUNE 16, 2023

Even in deals that ultimately do not include CVRs, they are frequently being discussed behind the scenes by buyers and sellers as a way to address a lack of alignment on valuation.

M&A 64

M&A Pharmaceutical Acquisitions Valuation 64

Cooley M&A

NOVEMBER 25, 2020

Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed.

Pharmaceutical 40

Pharmaceutical Media Mergers 40

How2Exit

MARCH 31, 2024

Get the Insider Tips You Need to Secure Your Deal - Watch Here rn rn About the Guest(s): rn Patrick O'Connell is an experienced mergers and acquisitions (M&A) advisor with a profound depth of knowledge in buying and selling small businesses valued between one to $20 million. b' E200: Buying or Selling a Small Business?

Business 130

Business Mergers and Acquisitions Securities M&A 130

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52